NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
1.770
-0.100 (-5.35%)
At close: Mar 5, 2026, 4:00 PM EST
1.750
-0.020 (-1.13%)
Pre-market: Mar 6, 2026, 8:47 AM EST
NRx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for NRx Pharmaceuticals stock have an average target of 31.5, with a low estimate of 18 and a high estimate of 48. The average target predicts an increase of 1,679.66% from the current stock price of 1.77.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRx Pharmaceuticals stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $45 | Strong Buy | Maintains | $40 → $45 | +2,442.37% | Mar 3, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +1,312.43% | Feb 18, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,820.90% | Feb 17, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +1,312.43% | Jan 15, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,820.90% | Jan 5, 2026 |
Financial Forecast
Revenue This Year
12.04M
Revenue Next Year
114.09M
from 12.04M
Increased by 847.91%
EPS This Year
-1.56
from -2.36
EPS Next Year
0.13
from -1.56
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 18.4M | 253.5M | ||||
| Avg | 12.0M | 114.1M | ||||
| Low | 2.9M | 39.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 2,005.9% | ||||
| Avg | - | 847.9% | ||||
| Low | - | 225.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -1.49 | 0.14 | ||
| Avg | -1.56 | 0.13 | ||
| Low | -1.65 | 0.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.